BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32004486)

  • 1. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
    Tambaro FP; Wierda WG
    Lancet Haematol; 2020 Feb; 7(2):e168-e176. PubMed ID: 32004486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
    Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
    Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
    Fischer K; Al-Sawaf O; Hallek M
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Gribben JG
    Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
    Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
    Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
    Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
    Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 15. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].
    Burghi G; Berrutti D; Manzanares W
    Med Intensiva; 2011 Apr; 35(3):170-8. PubMed ID: 21112673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Lampson BL; Davids MS
    Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
    Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
    Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
    Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.